Since its discovery in 2006 by Oh-I and colleagues, NUCB2/<em>nesfatin</em>-<em>1</em> encoded by nucleobindin-2 (NUCB2) has drawn sustained attention as reflected in over 500 publications. Among those, more than half focused on the alterations of food intake, body weight and metabolism (glucose, fat) induced by <em>nesfatin</em>-<em>1</em> and/or NUCB2/<em>nesfatin</em>-<em>1</em>. In the current review we discuss the existing literature focusing on NUCB2/<em>nesfatin</em>-<em>1</em>'s influence on food intake, body weight and glucose as well as fat metabolism and highlight gaps in knowledge.

To investigate the serum levels of <em>nesfatin</em>-<em>1</em> and galanin in patients with metabolic syndrome (MetS), and also to show their association with the parameters of the disease. Methods: We performed a case-control study with 84 participants (44 patients with MetS diagnosed according to the American Heart Association/National Heart, Lung, and Blood Institute and International Diabetes Federation criteria and 40 control group) were recruited from King Abdulaziz University Hospital, Jeddah, Saudi Arabia, between October 20<em>1</em>4 and June 20<em>1</em>5. Anthropometric parameters, biochemical markers as well as <em>nesfatin</em>-<em>1</em> and galanin were measured. Results: <em>Nesfatin</em>-<em>1</em> levels were found to be significantly lower and galanin levels significantly higher in MetS group compared to the control group. A significant negative correlation between serum <em>nesfatin</em>-<em>1</em> and weight, waist circumference, and body mass index were observed. A significant positive correlation between serum galanin and with fasting blood glucose, glycosylated hemoglobin, homeostasis model assessment-insulin resistance, and triglycerides. Conclusion: Our findings indicated a lower level of <em>nesfatin</em>-<em>1</em> and a higher level of galanin in patients with MetS, suggesting a role of these neuropeptides in the pathogenesis of this disease.

Little is known about the influence of central <em>nesfatin</em>-<em>1</em> on lipid metabolism under diabetic conditions. The main objective of this study was to characterize the mechanisms by which central <em>nesfatin</em>-<em>1</em> regulates lipid metabolism in streptozotocin (STZ)-induced type 2 diabetes mellitus (T2DM) and whether the sympathetic nervous system is involved. Male Kunming mice were fed high-fat diets (HFDs) and were treated twice with low-dose STZ (<em>1</em>00 mg/kg, intraperitoneal [IP]) to generate the T2DM model. Pharmacological adrenergic blockage (phentolamine <em>1</em>0 mg/kg, propranolol 0.0<em>1</em>7 mmol) and surgical denervation of sympathetic nervous system of the hindlimb and inguinal fat were used to block nerve conduction to determine whether the effect of central <em>nesfatin</em>-<em>1</em> required the hypothalamic-sympathetic nervous system axis. Plasma free fatty acid (FFA) and insulin levels were measured. AMP-activated protein kinase (AMPK) levels in skeletal muscle and hormone-sensitive lipase and adipose triglycerides lipase (HSL/ATGL) levels in white adipose tissue (WAT) were measured using western blot. mRNA expression of AMPK was measured. We found that there were significantly fewer NUCB2/<em>nesfatin</em>-<em>1</em> immunoreactive neurons in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) in T2DM mice. Central <em>nesfatin</em>-<em>1</em> administration decreased levels of plasma FFA significantly and activated AMPK to enhance fatty-acid oxidation in skeletal muscle in T2DM mice. In addition, HSL and ATGL were significantly activated during triglyceride mobilization in WAT triggered by central <em>nesfatin</em>-<em>1</em> administration. Adrenergic blockade and morphological denervation of the sciatic and femoral nerves reduced these changes. Taken together, these data suggest that central <em>nesfatin</em>-<em>1</em> regulates peripheral lipid metabolism in type 2 diabetes via the sympathetic nervous system.

Introduction. Short bowel syndrome can crop up if more than 50% of small intestine is resected or when less than <em>1</em>00 cm of small bowel is left. Glutamine is the main food source of enterocytes. Curcumin has protective effects on intestinal ischemia-reperfusion damage. <em>Nesfatin</em>-<em>1</em> is a satiety molecule. It has protective effects on gastric mucosa. The primary purpose of this study is to compare effects of glutamine, curcumin, and <em>nesfatin</em>-<em>1</em> on the gastric serosal surface neomucosa formation on rats. Materials and Methods. 24 Wistar-Hannover rats were randomly divided into 4 groups and treated with saline, glutamine, curcumin, and <em>nesfatin</em>-<em>1</em> after ileogastric anastomosis. After <em>1</em>4 days all rats were euthanized, and blood was collected. En bloc resection of anastomotic part was performed for histopathological examination. Results. PDGF, TGF-β, and VEGF levels and neomucosa formation were higher in glutamine group (p = 0.003, p = 0.003, and p = 0.025). Glutamine promotes the intestinal neomucosa formation on the gastric serosal surface and augments growth factors essential for neomucosa formation on rats. Conclusion. Glutamine may be used in short bowel syndrome for increasing the absorption surface area. But that needs to be determined by adequately powered clinical trials.

Leptin, leptin receptor, proopiomelanocortin, prohormone convertase <em>1</em>, melanocortin-4 receptor, melanocortin-3 receptor, brain-derived neurothrophic factor, neurotrophic tyrosine receptor kinase type 2, and single minded <em>1</em> genes, which are the genes that have been shown to cause monogenic obesity, are related to the leptin-melanocortin system. Congenital prohormone convertase <em>1</em> deficiency is a very rare syndrome characterized by early-onset obesity, small intestinal dysfunction, impaired glucose homeostasis, and disrupted prohormone processing. Obesity phenotype seen in this syndrome is known to be due to reduced melanocortin signaling in the hypothalamus which arises as a result of impaired processing of proopiomelanocortin. However, prohormone convertase <em>1</em> cleaves a number of other neuropeptides involved in feeding behavior and impaired cleavage of these neuropeptides, particularly NUCB2/<em>nesfatin</em>, may be a contributing factor for development of obesity in these cases. Until now, in prohormone convertase <em>1</em> deficient patients, low serum <em>nesfatin</em>-<em>1</em> levels have not been mentioned to be a possible cause of obesity, we suggest that in these patients low levels of anorexigenic peptid <em>nesfatin</em>-<em>1</em> might be another facilitating factor for development of obesity.

<em>Nesfatin</em>-<em>1</em> (Nes-<em>1</em>), an 82-amino acid protein cleaved from nucleobindin-2, has been suggested to play a role in ingestive behaviors. Intracerebroventricular (icv) injections of Nes-<em>1</em> reduce water intake, although the sites of action for this effect are not known. Two series of experiments were done to identify potential sites of action of Nes-<em>1</em> in drinking behavior. In the first series, icv injections of Nes-<em>1</em> were made in urethane-anesthetized rats to investigate the distribution of neurons containing Fos-like immunoreactivity (Fos-ir) within the forebrain. Circumventricular organs, including subfornical organ (SFO), were found to contain neurons expressing Fos-ir. Additionally, several hypothalamic, thalamic and limbic nuclei also contained Fos-labeled neurons. As SFO is a pivotal central site in the regulation of water intake, a second series of experiments was done to investigate the role of direct injections of Nes-<em>1</em> into SFO on water intake in conscious, freely moving rats. Nes-<em>1</em> (2pmol) injections into SFO induced an increase in water intake compared to vehicle injections. However, when food was made available for ingestion after the Nes-<em>1</em> injection, the dipsogenic effects of Nes-<em>1</em> were attenuated. Additionally, the drinking response to Nes-<em>1</em> was found to be more potent than that observed after injections of ANG II into SFO. Neither simultaneous injections ANG II nor the ANG II type-<em>1</em> receptor blocker losartan affected the Nes-<em>1</em> dipsogenic response. Taken together, these results suggest that Nes-<em>1</em> is a potent dipsogenic agent in SFO, and that Nes-<em>1</em> may act independently of the SFO angiotensinergic system to elicit the dipsogenic effect.

BACKGROUND

<em>Nesfatin</em>-<em>1</em> is a protein derived from a precursor molecule of the nucleobindin-2 gene, and acts as an anorexigenic peptide on food intake behavior, and its level isinfluenced by nutritional status, food composition [fat and carbohydrate (CHO)], and physical exercise.

OBJECTIVE

The aim of this study was to investigate the effects of 6 weeks of treadmill running (at high intensity) program with and without zizyphus jujuba (high carbohydrate content) crud extraction on liver nesfatin-<em>1</em>, ATP, glycogen, and its plasma concentrations in female rats.

METHODS

Twenty-eight Wistar female rats (6-8 weeks old<em>1</em>00-<em>1</em>20 g of weight) were randomly assigned to saline-control (SC), saline-training (ST), zizyphus jujuba-control (ZJC), and zizyphus jujuba-training (ZJT) groups. Rats ran on a motor-driven treadmill at 35 m/min, 60 min/day, 5 days/week for 6 weeks. Animals received ZJ extraction and saline at the dose of <em>1</em>.25 mL/<em>1</em>00g of body weight. Seventy-two hours after the last training session rats were killed, a portion of liver excited, and plasma was collected for nesfatin-<em>1</em>, ATP, and glycogen measurements. A one-way ANOVA method, and Pearson correlation were employed. P < 0.05 was considered as significant.

RESULTS

A higher and significant liver nesfatin-<em>1</em> level was found in ZJ groups (p < 0.005), but plasma nesfatin-<em>1</em> responded differently. Changes in liver nesfatin-<em>1</em> were accompanied with an increase in liver glycogen,but not ATP contents.

CONCLUSIONS

The Findings indicate that higher liver nesfatin-<em>1</em> and glycogen content by ZJ extraction might be due to the ZJ high CHO content, and it could be consideredas an anti-appetite herb.

BACKGROUND

This study aimed to examine the effects of <em>nesfatin</em>-<em>1</em> on thoracic aorta vasoreactivity and to investigate the inotropic and chronotropic effects of <em>nesfatin</em>-<em>1</em> on the spontaneous contractions of the isolated rat atria.

METHODS

Isolated right atria and thoracic aorta were used in organ baths. The reactivity of the thoracic aorta was evaluated by potassium chloride (KCl), phenylephrine (Phe), acetylcholine (ACh), and sodium nitroprusside (SNP). The effects of <em>nesfatin</em>-<em>1</em> on the spontaneous contractions of the rat atria were also examined.

RESULTS

Nesfatin-<em>1</em> (0.<em>1</em>-<em>1</em>00 ng/ml) produced a concentration-dependent relaxation response in rat thoracic aorta. The relaxant responses to <em>nesfatin</em>-<em>1</em> were inhibited by the removal of endothelium, NO synthase blocker N-nitro-L-arginine methyl ester (L-NAME, <em>1</em>0-4 M), and soluble guanylate cyclase inhibitor <em>1</em>H-[<em>1</em>,2,4]oxadiazolo[4,3-a]quinoxalin-<em>1</em>-one (ODQ, <em>1</em>0-5 M). Nesfatin-<em>1</em> (<em>1</em>0 ng/ml, 30 min) increased the relaxation responses to either ACh or SNP, and the contractile response to both Phe and KCl did not significantly change in the arteries that were incubated with <em>nesfatin</em>-<em>1</em> compared with the controls. The thoracic aorta contractions induced by the stepwise addition of Ca2+ to a high KCl solution with no Ca2+ were not significantly changed by <em>nesfatin</em>-<em>1</em>. Under calcium-free conditions, the contractions of the thoracic aorta rings incubated with <em>nesfatin</em>-<em>1</em> in response to Phe were not significantly lower than those of the rings from the control rats. Nesfatin-<em>1</em> showed positive inotropic and chronotropic effects on rat atria.

CONCLUSIONS

Nesfatin-<em>1</em> significantly changed the vascular responsiveness in rat thoracic aorta and produced positive inotropic and chronotropic effects on rat atria.

<em>Nesfatin</em>-<em>1</em> is one of several brain-gut peptides that have a close relationship with the central dopaminergic system. Our previous studies have shown that <em>nesfatin</em>-<em>1</em> is capable of protecting nigral dopaminergic neurons against <em>1</em>-methyl-4-phenyl-<em>1</em>,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. A recent study also revealed a reduced blood level of <em>nesfatin</em>-<em>1</em> in patients with Parkinson's disease (PD). The current study was designed to investigate whether reduced <em>nesfatin</em>-<em>1</em> in cerebrospinal fluid (CSF) induces nigrostriatal system degeneration. An intra-cerebroventricular (ICV) injection technique was used to administer anti-<em>nesfatin</em>-<em>1</em> antibody directly into the lateral ventricle of the brain. Enzyme-linked immunosorbent assay (ELISA) results showed that ICV injection of anti-<em>nesfatin</em>-<em>1</em> antibody into the lateral ventricle of the brain once daily for 2 weeks caused a significant reduction in <em>nesfatin</em>-<em>1</em> levels in the CSF (93.<em>1</em>%). Treatment with anti-<em>nesfatin</em>-<em>1</em> antibody resulted in a substantial loss (23%) of TH-positive (TH+) dopaminergic neurons in the substantia nigra pars compacta (SNpc), as shown by immunofluorescence staining, a depletion in dopamine and its metabolites in the striatum detected by high-performance liquid chromatography (HPLC), and obvious nuclear shrinkage and mitochondrial lesions in dopaminergic neurons in the SNpc detected by transmission electron microscopy (TEM). Furthermore, the results from our Western blot and ELISA experiments demonstrated that anti-<em>nesfatin</em>-<em>1</em> antibody injection induced an upregulation of caspase-3 activation, increased the expression of <i>p</i>-ERK, and elevated brain-derived neurotrophic factor (BDNF) levels in the SNpc. Taken together, these observations suggest that reduced <em>nesfatin</em>-<em>1</em> in the brain may induce nigrostriatal dopaminergic system degeneration; this effect may be mediated <i>via</i> mitochondrial dysfunction-related apoptosis. Our data support a role of <em>nesfatin</em>-<em>1</em> in maintaining the normal physiological function of the nigrostriatal dopaminergic system.

<strong class="sub-title"> Keywords: </strong> Parkinson’s disease; apoptosis; degeneration; dopaminergic neuron; mitochondrion; <em>nesfatin</em>-<em>1</em>; nigrostriatal system.

<em>Nesfatin</em>-<em>1</em> (Nesf-<em>1</em>) was identified as an anorexigenic and well conserved molecule in rodents and fish. While tissue distribution of NUCB2 (Nucleobindin 2)/Nesf-<em>1</em> is discretely known in vertebrates, reports on ontogenetic expression are scarce. Here, we examine the age-related central and peripheral expression of NUCB2/Nesf-<em>1</em> in the teleost African turquoise killifish <i>Nothobranchius</i><i>furzeri</i>, a consolidated model organism for aging research. We focused our analysis on brain areas responsible for the regulation of food intake and the rostral intestinal bulb, which is analogous of the mammalian stomach. We hypothesize that in our model, the stomach equivalent structure is the main source of NUCB2 mRNA, displaying higher expression levels than those observed in the brain, mainly during aging. Remarkably, its expression significantly increased in the rostral intestinal bulb compared to the brain, which is likely due to the typical anorexia of aging. When analyzing the pattern of expression, we confirmed the distribution in diencephalic areas involved in food intake regulation at all age stages. Interestingly, in the rostral bulb, NUCB2 mRNA was localized in the lining epithelium of young and old animals, while Nesf-<em>1</em> immunoreactive cells were distributed in the submucosae. Taken together, our results represent a useful basis for gaining deeper knowledge regarding the mechanisms that regulate food intake during vertebrate aging.

BACKGROUND

<em>Nesfatin</em> <em>1</em> is a newly identified peptide structured satiety hormone that is claimed to be responsible for the provision of appetite and metabolic regulation in hypothalamus. The change in appetite and energy is a well-known clinical feature of affective disorders and within treatment. We aimed to investigate serum <em>nesfatin</em> <em>1</em> level in patients with bipolar disorder who were in manic episode and the influences of treatment modalities on <em>nesfatin</em> <em>1</em> level.

METHODS

Sixty eight patients were elected and were divided into two groups as: antipsychotic treatment (haloperidol <em>1</em>0-30 mg/daily+quetiapine <em>1</em>00-900 mg/daily) arm and ECT+antipsychotic treatment arm. And 30 healthy controls were included in the study.

RESULTS

There was no significant difference according to mean age between patients and controls. Initial <em>nesfatin</em> <em>1</em> levels in patients and in both subgroups of patients were statistically lower than in healthy control group. The initial level of <em>nesfatin</em> <em>1</em> between ECT+antipsychotic and pure antipsychotic patient groups was not statistically significant. We found a trend of increment in <em>nesfatin</em> <em>1</em> level after treatment in both patient groups.

CONCLUSIONS

This study is the first that revealed significantly lower <em>nesfatin</em> <em>1</em> level in manic episode than healthy controls. ECT+antipsychotic and antipsychotic treatments have no significant effects on <em>nesfatin</em> <em>1</em> level after manic episode treatment. These findings should be interpreted cautiously because of small sample size and being drug free only for one week.

Studies on appetite hormones in chronic kidney disease (CKD) patients appear of interest since these compounds may be implicated in reduced appetite, loss of weight and/or malnutrition. Anorexia seems to be related to many hormones that act in central nervous system, like leptin, obestatin and others, and more recently, was discovered a hypothalamus secreted protein that conduces to a decrease on food intake and to an increase on energetic waste, called <em>nesfatin</em>-<em>1</em>. This peptide has been studied in diabetes, mean arterial pressure and cardiovascular function, anxiety- and/or fear-related responses and inflammation, but there are no studies about a possible relationship with CKD. Therefore, considering the negative impact of anorexia and malnutrition in morbidity and mortality of CKD patients and the interest in new treatments findings for dialysis population, this review will discuss recent information about <em>nesfatin</em>-<em>1</em> and its possible role in CKD patients.

Recently, the hypothalamic 82-aa peptide <em>Nesfatin</em>-<em>1</em> received notable attention for its anorexigenic and anti-hyperglycemic properties. In mammalian hypothalamus, <em>Nesfatin</em>-<em>1</em> is expressed, together with the precursor Nucleobindin 2 (NUCB2), in regions controlling water-food intake, body weight, and glucose homeostasis. The peptide is also peripherally expressed, as shown in the rat heart, in which it is present together with NUCB2. In addition to a central modulation of nutrition and energy balance, and of the nervous circuits responsible for blood pressure and heart rate control, <em>Nesfatin</em>-<em>1</em> also acts peripherally on several districts, including the cardiovascular (CV) system. Accordingly, the peptide is regarded with interest as a multifunctional hormone not only linked to alimentary homeostasis. This review aims to analyze the literature on <em>Nesfatin</em>-<em>1</em>, with focus on its emerging CV activity. Few available studies show that the peptide affects energy metabolism of murine and human cardiomyocytes, by eliciting insulin-like effects. On the ex vivo rat heart, it directly depresses contractility and relaxation via cGMP, PKG and ERK<em>1</em>/2, and limits ischemia/reperfusion (I/R) damage, acting in post-conditioning protection. <em>Nesfatin</em>-<em>1</em> actions are proposed to involve an unknown G-protein coupled receptor. However, in the rat heart, functional studies, co-immunoprecipitation and local sequence alignment analyses suggest an interaction with the Natriuretic Peptide Receptor-type A (NPR-A). These data open up novel perspectives to clarify not only the biological significance of the peptide, but also its putative biomedical potential in the presence of nutrition-dependent cardiovascular diseases.

To explore the role of <em>nesfatin</em>-<em>1</em> in regulating male reproductive function during energy balance variation, we employed an obese mouse model which was first induced by a high-fat diet (HFD) and followed by interventions of a normal diet (ND) and/or moderate exercise, and then serum reproductive hormones of male mice, hypothalamic nucleobindin 2 (NUCB2)/<em>nesfatin</em>-<em>1</em>, inflammatory factors, and gonadotropin-releasing hormone (GnRH) levels were tested. Our findings showed that both serum <em>nesfatin</em>-<em>1</em>, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone (T) levels and hypothalamic NUCB2/<em>nesfatin</em>-<em>1</em> and Gnrh mRNA levels were reduced, whereas, the mRNA and protein levels of hypothalamic tumor necrosis factor-α (TNF-α), interleukin (IL)-<em>1</em>β, inhibitor kappa B kinase β (IKKβ), and nuclear factor (NF)-κB were increased in obese male mice. Diet, exercise, and diet combined with exercise interventions reversed the decreases in serum <em>nesfatin</em>-<em>1</em>, FSH, LH, and T levels; increased hypothalamic NUCB2/<em>nesfatin</em>-<em>1</em> and Gnrh mRNA levels; and reduced hypothalamic TNF-α, IL-<em>1</em>β, IKKβ, and NF-κB levels. These changes were accompanied by reduced adiposity, and these effects were more obvious in the diet combined with exercise group. Overall, our findings suggested that the hypogonadotropic hypogonadism associated with obesity may be induced by reduced hypothalamic NUCB2/<em>nesfatin</em>-<em>1</em> levels, which attenuated the stimulatory effect on GnRH directly or indirectly by suppressing its anti-inflammatory effect in the brain. Diet and/or exercise interventions were able to alleviate the hypogonadotropic hypogonadism associated with obesity, potentially by increasing hypothalamic NUCB2/<em>nesfatin</em>-<em>1</em> levels.

OBJECTIVE

To establish a rat model of anxiety-like gastric hypersensitivity (GHS) of functional dyspepsia (FD) induced by novel sequential stress.

METHODS

Animal pups were divided into two groups from postnatal day 2: controls and the sequential-stress-treated. The sequential-stress-treated group received maternal separation and acute gastric irritation early in life and restraint stress in adulthood; controls were reared undisturbed with their mothers. Rats in both groups were followed to adulthood (8 wk) at which point the anxiety-like behaviors and visceromotor responses to gastric distention (20-<em>1</em>00 mmHg) and gastric emptying were tested. Meanwhile, alterations in several anxiety-related brain-stomach modulators including 5-hydroxytryptamine (5-HT), γ-aminobutyric acid (GABA), brain-derived neurotrophic factor (BDNF) and <em>nesfatin</em>-<em>1</em> in the rat hippocampus, plasma and gastric fundus and the 5-HT<em>1</em>A receptor (5-HT<em>1</em>AR) in the hippocampal CA<em>1</em> subfield and the mucosa of the gastric fundus were examined.

RESULTS

Sequential-stress-treated rats simultaneously demonstrated anxiety-like behaviors and GHS in dose-dependent manner compared with the control group. Although rats in both groups consumed similar amount of solid food, the rate of gastric emptying was lower in the sequential-stress-treated rats than in the control group. Sequential stress significantly decreased the levels of 5-HT (5<em>1</em>.9<em>1</em> ± <em>1</em>.88 vs <em>1</em>04.2<em>1</em> ± 2.88, P < 0.0<em>1</em>), GABA (2.38 ± 0.<em>1</em>6 vs 5.0<em>1</em> ± 0.<em>1</em>3, P < 0.0<em>1</em>) and BDNF (304.40 ± <em>1</em>0.<em>1</em>6 vs 698.<em>1</em>7 ± 27.9<em>1</em>, P < 0.0<em>1</em>) in the hippocampus but increased the content of <em>nesfatin</em>-<em>1</em> (<em>1</em>96<em>1</em>.38 ± 56.89 vs <em>1</em>007.50 ± 33.05, P < 0.0<em>1</em>) in the same site; significantly decreased the levels of 5-HT (47.82 ± 2.29 vs 89.45 ± 2.6<em>1</em>, P < 0.0<em>1</em>) and BDNF (257.05 ± <em>1</em>2.89 vs 536.7<em>1</em> ± 20.73, P < 0.0<em>1</em>) in the plasma but increased the content of <em>nesfatin</em>-<em>1</em> in it (<em>1</em>39<em>1</em>.75 ± 42.77 vs 737.88 ± 33.<em>1</em>5, P < 0.0<em>1</em>); significantly decreased the levels of 5-HT (4<em>1</em>.<em>1</em>5 ± <em>1</em>.8<em>1</em> vs 89.<em>1</em>7 ± 2.3<em>1</em>, P < 0.0<em>1</em>) and BDNF (226.49 ± <em>1</em>2.<em>1</em>0 vs 55<em>1</em>.36 ± <em>1</em>6.47, P < 0.0<em>1</em>) in the gastric fundus but increased the content of <em>nesfatin</em>-<em>1</em> in the same site (<em>1</em>534.75 ± 38.52 vs 8<em>1</em>9.63 ± 38.04, P < 0.0<em>1</em>). The expressions of 5-HT<em>1</em>AR in the hippocampal CA<em>1</em> subfield and the mucosa of the gastric fundus were down-regulated measured by IHC (Optical Density value: Hippocampus <em>1</em>5253.50 ± 760.35 vs 2<em>1</em><em>1</em>49.75 ± 834.<em>1</em>3; gastric fundus <em>1</em>5865.25 ± 52<em>1</em>.24 vs 23865.75 ± <em>1</em>868.60; P < 0.05, respectively) and WB (0.38 ± 0.0<em>1</em> vs 0.57 ± 0.03, P < 0.0<em>1</em>) (n = 8 in each group).

CONCLUSIONS

Sequential stress could induce a potential rat model of anxiety-like GHS of FD, which could be used to research the mechanisms of this intractable disease.

The classic concept of how pituitary GH is regulated by somatostatin and GHRH has changed in recent years, following the discovery of peripheral hormones involved in the regulation of energy homeostasis and mineral homeostasis. These hormones are ghrelin, <em>nesfatins</em>, and klotho. Ghrelin is an orexigenic hormone, released primarily by the gastric mucosa, although it is widely expressed in many different tissues, including the central nervous system and the pituitary. To be active, ghrelin must bind to an n-octanoyl group (n = 8, generally) on serine 3, forming acyl ghrelin which can then bind and activate a G-protein-coupled receptor leading to phospholipase C activation that induces the formation of inositol <em>1</em>,4,5-triphosphate and diacylglycerol that produce an increase in cytosolic calcium that allows the release of GH. In addition to its direct action on somatotrophs, ghrelin co-localizes with GHRH in several neurons, facilitating its release by inhibiting somatostatin, and acts synergistically with GHRH stimulating the synthesis and secretion of pituitary GH. Gastric ghrelin production declines with age, as does GH. Klotho is an anti-aging agent, produced mainly in the kidneys, whose soluble circulating form directly induces GH secretion through the activation of ERK<em>1</em>/2 and inhibits the inhibitory effect that IGF-I exerts on GH. Children and adults with untreated GH-deficiency show reduced plasma levels of klotho, but treatment with GH restores them to normal values. Deletions or mutations of the <i>Klotho</i> gene affect GH production. <em>Nesfatins</em> <em>1</em> and 2 are satiety hormones, they inhibit food intake. They have been found in GH3 cell cultures where they significantly reduce the expression of <i>gh</i> mRNA and that of pituitary-specific positive transcription factor <em>1</em>, consequently acting as inhibitors of GH production. This is a consequence of the down-regulation of the cAMP/PKA/CREB signaling pathway. Interestingly, <em>nesfatins</em> eliminate the strong positive effect that ghrelin has on GH synthesis and secretion. Throughout this review, we will attempt to broadly analyze the role of these hormones in the complex world of GH regulation, a world in which these hormones already play a very important role.

Keywords: GHRH; IGF-I; ghrelin; growth hormone; klotho; nesfatins; somatostatin.

<em>Nesfatin</em>-<em>1</em> (NESF) and NESF-like peptide (NLP), encoded in nucleobindin 2 and <em>1</em> (NUCB2 and NUCB<em>1</em>), respectively, are orphan ligands and metabolic factors. We hypothesized that NESF and NLP suppress growth hormone (GH) synthesis, and aimed to determine whether mammalian somatotrophs are a source and site of action of these peptides. Using immortalized rat somatotrophs (GH3 cells), NUCB expression was determined by qPCR, immunofluorescence and Western blot. NESF and NLP binding to GH3 cells was tested using fluorescence imaging. Both time- and concentration-dependent studies were performed to test whether NESF and NLP affect GH. Moreover, the ability of these peptides to modulate the effects of ghrelin, and cell-signaling pathways were studied. GH3 cells express NUCB mRNAs and protein. Labeled NESF and NLP bind to the surface of GH3 cells, and incubation with either NESF or NLP decreased GH mRNA and protein expression, downregulated pit-<em>1</em> mRNA, and blocked the GH stimulatory effects of ghrelin. Pre-incubation with either of these peptides reduced CREB phosphorylation by an AC-activator, but not when PKA was directly activated by a cAMP analog. Our results indicate that rat somatotrophs are a source of NUCBs, and that NESF and NLP downregulate GH synthesis through the AC/PKA/CREB signaling pathway.

Nucleobindin-<em>1</em> has high sequence similarity to nucleobindin-2, which encodes the anorectic and metabolic peptide, <em>nesfatin</em>-<em>1</em>. We previously reported a <em>nesfatin</em>-<em>1</em>-like peptide (NLP), anorectic in fish and insulinotropic in mice islet beta-like cells. The main objective of this research was to determine whether NLP is a metabolic regulator in male Wistar rats. A single intraperitoneal (IP) injection of NLP (<em>1</em>00 μg/kg BW) decreased food intake and increased ambulatory movement, without causing any change in total activity or energy expenditure when compared to saline-treated rats. Continuous subcutaneous infusion of NLP (<em>1</em>00 μg/kg BW) using osmotic mini-pumps for 7 days caused a reduction in food intake on days 3 and 4. Similarly, water intake was also reduced for two days (days 3 and 4) with the effect being observed during the dark phase. This was accompanied by an increased RER and energy expenditure. However, decreased whole-body fat oxidation, and total activity were observed during the long-term treatment (7 days). Body weight gain was not significantly different between control and NLP infused rats. The expression of mRNAs encoding adiponectin, resistin, ghrelin, cholecystokinin and uncoupling protein <em>1</em> (UCP<em>1</em>) were significantly upregulated, while leptin and peptide YY mRNA expression was downregulated in NLP-treated rats. These findings indicate that administration of NLP at <em>1</em>00 μg/kg BW reduces food intake and modulates whole body energy balance. In summary, NLP is a novel metabolic peptide in rats.

The hypothalamus controls metabolism and feeding behaviour via several signals with other tissues. Exercise and supplements can change hypothalamic signalling pathways, so the present study investigated the influence of eccentric resistance training and β-hydroxy-β-methylbutyrate free acid supplementation on PGC-<em>1</em>α expression, serum irisin, <em>nesfatin</em>-<em>1</em> and resistin concentrations. Thirty-two male rats (8 weeks old, 200±<em>1</em>7 g body mass) were randomly allocated to control, β-hydroxy-β-methylbutyrate free acid supplementation (HMB), eccentric resistance training (ERT), and β-hydroxy-β-methylbutyrate free acid supplementation plus eccentric resistance training (HMB+ERT) groups. Training groups undertook eccentric resistance training (6 weeks, 3 times a week) and supplement groups consumed β-hydroxy-β-methylbutyrate free acid (HMB-FA) orally (76 mg kg^-<em>1</em> day^-<em>1</em>). Twenty-four hours after the last training session, serum and triceps brachii muscle samples were collected and sent to the laboratory for analysis. Two-way ANOVA and Pearson correlation were employed (significance level: <i>P</i><0.05). The results showed that eccentric resistance training increases skeletal muscle <i>PGC-<em>1</em>α</i> gene expression, as well as serum levels of irisin and <em>nesfatin</em>-<em>1</em> (<i>P</i>=0.00<em>1</em>). Eccentric resistance training decreased the serum concentration of resistin (<i>P</i>=0.00<em>1</em>). HMB-FA supplementation increased skeletal muscle <i>PGC-<em>1</em>α</i> gene expression (<i>P</i>=0.002), as well as the serum concentration of irisin and <em>nesfatin</em>-<em>1</em> (<i>P</i>=0.00<em>1</em>), but decreased the serum concentration of resistin (<i>P</i>=0.00<em>1</em>). Significant correlations were observed between <i>PGC-<em>1</em>α</i> gene expression and serum concentrations of irisin, <em>nesfatin</em>-<em>1</em> and resistin. HMB-FA supplementation with eccentric resistance training may induce crosstalk between peptide release from other tissues and increases maximal muscle strength. The combination of the two interventions had a more substantial effect than each in isolation.

Genetic research has revealed pro-opiomelanocortin (POMC) to be a fundamental regulator of energy balance and body weight in mammals. Within the brain, POMC is primarily expressed in the arcuate nucleus of the hypothalamus (ARC), while a smaller population exists in the brainstem nucleus of the solitary tract (POMCNTS). We performed a neurochemical characterization of this understudied population of POMC cells using transgenic mice expressing green fluorescent protein (eGFP) under the control of a POMC promoter/enhancer (PomceGFP). Expression of endogenous Pomc mRNA in NTS PomceGFP cells was confirmed using fluorescence-activating cell sorting (FACS) followed by quantitative PCR. In situ hybridization histochemistry of endogenous Pomc mRNA and immunohistochemical analysis of eGFP revealed that POMC is primarily localized within the caudal NTS. Neurochemical analysis indicated that POMCNTS is not co-expressed with tyrosine hydroxylase (TH), glucagon-like peptide <em>1</em> (GLP-<em>1</em>), cholecystokinin (CCK), brain-derived neurotrophic factor (BDNF), <em>nesfatin</em>, nitric oxide synthase <em>1</em> (nNOS), seipin or choline acetyltransferase (ChAT) cells, whereas <em>1</em>00% of POMCNTS is co-expressed with transcription factor paired-like homeobox2b (Phox2b). We observed that 20% of POMCNTS cells express receptors for adipocyte hormone leptin (LepRbs) using a PomceGFP:LepRbCre:tdTOM double-reporter line. Elevations in endogenous or exogenous leptin levels increased the in vivo activity (c-FOS) of a small subset of POMCNTS cells. Using ex vivo slice electrophysiology, we observed that this effect of leptin on POMCNTS cell activity is post-synaptic. These findings reveal that a subset of POMCNTS cells are responsive to both changes in energy status and the adipocyte hormone leptin, findings of relevance to the neurobiology of obesity.

Sodium valporate (VPA), a broad-spectrum inhibitor of histone deacetylases (HDACs), increased ghrelin whereas decreased <em>nesfatin</em>-<em>1</em> in mice fed normal chow diet or high-fat diet. Alterations in ghrelin and nucleobindin 2/<em>nesfatin</em>-<em>1</em> were mediated by HDAC5 but not HDAC4. Activation of mTORC<em>1</em> significantly attenuated the effect of VPA on ghrelin and <em>nesfatin</em>-<em>1</em> levels. HDAC5 coimmunoprecipitated with raptor. Inhibition of HDAC5 by VPA, trichostatin A, or siHDAC5 markedly increased acetylation of raptor Lys840 and subsequent phosphorylation of raptor Ser792, resulting in suppression of mTORC<em>1</em> signaling. A raptor mutant lacking the Lys840 acetylation site showed a decrement in phosphorylation of raptor Ser792 and subsequent increase in mTORC<em>1</em> signaling. These alterations were associated with reciprocal changes in ghrelin and nucleobindin 2/<em>nesfatin</em>-<em>1</em> expression. These findings reveal HDAC5-mTORC<em>1</em> signaling as a novel mechanism in the differential regulation of gastric ghrelin and <em>nesfatin</em>-<em>1</em>.

<strong class="sub-title"> Background: </strong> <em>Nesfatin</em>-<em>1</em> is a novel peptide possessing pleiotropic metabolic effects. No-reflow phenomenon (NR) is a poor prognostic indicator occurring in around 30% of all patients undergoing primary percutaneous coronary interventions (pPCI). Inflammation and complexity of coronary artery disease (CAD) play pivotal roles in the pathogenesis of NR. In this study, we investigated the relationship between admission serum <em>nesfatin</em>-<em>1</em> level, NR and complexity of CAD assessed by SYNTAX-<em>1</em> (SS-<em>1</em>) and SYNTAX-2 (SS-2) scores in patients with ST-segment elevation myocardial infarction (STEMI) undergoing pPCI.

<strong class="sub-title"> Methods: </strong> A total of <em>1</em>74 STEMI patients who underwent pPCI were included in the study and divided into NR (n = 36) and normal flow (n = <em>1</em>38) groups. Serum <em>nesfatin</em>-<em>1</em> was measured by enzyme-linked immunosorbent assay. Seventy-eight consecutive age-, gender- and co-morbidity-matched patients undergoing coronary angiography with < 50% stenosis comprised the control group.

<strong class="sub-title"> Results: </strong> <em>Nesfatin</em>-<em>1</em> levels were significantly lower in the NR group compared to the normal flow and control groups (<em>1</em>0.8 ± 6.6 ng/mL vs. 34.9 ± 24 ng/mL vs. 43.6 ± 23.2 ng/mL, respectively, p < 0.00<em>1</em>). <em>Nesfatin</em>-<em>1</em> was significantly and inversely correlated with SS-<em>1</em> and SS-2 scores (r = -0.709 and r = -0.655, respectively, both p < 0.00<em>1</em>). Multivariate logistic regression analysis showed that <em>nesfatin</em>-<em>1</em> [odds ratio (OR) = 0.8<em>1</em>, 95% confidence interval (CI) = 0.708-0.936, p = 0.004] and glomerular filtration rate (OR = 0.94, 95% CI = 0.892-0.989, p = 0.0<em>1</em>8) were independently associated with NR. In the receiver operating characteristic analysis, <em>nesfatin</em>-<em>1</em> < <em>1</em>5.2<em>1</em> ng/mL predicted NR with 78.4% sensitivity and 72.2% specificity (area under the curve = 0.809, 95% CI = 0.70<em>1</em>-0.9<em>1</em>8, p < 0.00<em>1</em>).

<strong class="sub-title"> Conclusions: </strong> Admission <em>nesfatin</em>-<em>1</em> level is a potent predictor of NR in STEMI patients undergoing pPCI. Additionally, <em>nesfatin</em>-<em>1</em> has a robust and negative correlation with the complexity of CAD.

<strong class="sub-title"> Keywords: </strong> Acute myocardial infarction; <em>Nesfatin</em>-<em>1</em>; No-reflow phenomenon; SYNTAX score.

<strong class="sub-title"> Background: </strong> <em>Nesfatin</em>-<em>1</em>, a novel adipokine and dipeptidyl peptidase-4 (DPP4), a mam malian serine protease, are potent factors of atherosclerosis. In the present cross-sectional study, we investigated whether the plasma <em>nesfatin</em>-<em>1</em> and DPP4 is associated with the prevalence and severity of coronary artery disease (CAD) with and without diabetes mellitus (DM).

<strong class="sub-title"> Methods: </strong> We consecutively enrolled a total of 240 patients with significant CAD (previous revascularization or angiographically-proven coronary artery stenosis > 50%) presented with either unstable angina (UA, N = 76) or stable chronic CAD (SCAD, N = <em>1</em>65). 85 patients with at least 2 classical cardiovascular risk factors but without significant CAD served as controls. The severity of CAD was assessed using coronary angiography by the Gensini score. Clinical parameters, glycemic and lipid profile, high-sensitivity CRP (hsCRP), <em>nesfatin</em>-<em>1</em> and DPP4 levels were assayed.

<strong class="sub-title"> Results: </strong> No differences were found for age, sex, hypertension and diabetes distribution between groups. Low <em>nesfatin</em>-<em>1</em> levels were found in both CAD groups (UA & SCAD) with respect to controls. The difference between UA and SCAD groups was marginally non-significant. There was a significant increase of DPP4 along UA to SCAD and control groups. Differences between groups remained unchanged in non-diabetic participants. <em>Nesfatin</em>-<em>1</em> significantly correlated to hsCRP (r = - 0.287, p = 0.036), HOMA-IR (r = - 0.587, p = 0.007) and hyperlipidemia (r = - 0.33<em>1</em>, p = 0.034). DPP4 was significantly associated with hs-CRP (r = 0.353 p < 0.00<em>1</em>) and FPG (r = 0.202, p = 0.020) in univariate analysis, but those correlations were lost in multiple regression analysis. There was a negative correlation between <em>nesfatin</em>-<em>1</em> and the severity of CAD, quantified by the Gensini score (r = - 0.5<em>1</em><em>1</em>, p < 0.00<em>1</em>), but no association was found for DPP4.

<strong class="sub-title"> Conclusions: </strong> Serum DPP4 levels are increased in patients with CAD, while serum <em>nesfatin</em>-<em>1</em> levels have a negative association with both the incidence and the severity of CAD. These results are independent of the presence of diabetes mellitus. In addition, both peptides have a strong association with hsCRP. Trial registration ClinicalTrials.gov Identifier: <a href="http://clinicaltrials.gov/show/NCT00306<em>1</em>76" title="See in ClinicalTrials.gov">NCT00306<em>1</em>76</a>.

<strong class="sub-title"> Keywords: </strong> Coronary artery disease; Dipeptidyl peptidase-4; <em>Nesfatin</em>-<em>1</em>; Unstable angina.